Leisure, Lifestyle & Wellness
Recording, sharing videos now possible on Twitter's Direct Messages

A GIF button and a video support don't do much to fix those longstanding issues but they may bring the website up to compete with Facebook and Google

 

Aiming to take Twitter to a new level amid an existential crisis, the micro-blogging website is now bringing video support to Direct Messages.
 
"The company keeps plugging away at basic features to bring the service up to speed with competitors like Facebook Messenger. Following the addition of a GIF button on Wednesday, Twitter is rolling out this feature globally to iOS and Android smartphones," The Verge quoted the company as saying on Wednesday.
 
However, on twitter.com, user will be to send videos from within Direct Messages threads, but won't be able to record them directly on the website.
 
A GIF button and a video support don't do much to fix those longstanding issues but they may bring the website up to compete with Facebook and Google.
 
Recently, Twitter introduced a new timeline feature that allows users to never miss important tweets from people they follow by giving an option to see the best tweets first. 
 
The rest of the tweets are displayed right underneath.
 
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.

User

Cipla acquires two US drug firms for $550 mn

The company had informed Bombay Stock Exchange on Sep 4, last year that the cash consideration payable for Invagen is $500 million and for Exelan it is $50 million

 

Drug major Cipla has acquired two US-based firms -- InvaGen Pharmaceuticals and Exelan Pharmaceuticals -- for $550 million, the company said in a regulatory filing here on Thursday.
 
"The acquisition was made by Cipla's UK arm Cipla through a wholly-owned special purpose vehicle which would merge into InvaGen Pharmaceuticals after the acquisition. The combined revenue for the two companies for the year-ended 2015 is over $230 million," the company said in a statement.
 
The company had informed Bombay Stock Exchange on Sep 4, last year that the cash consideration payable for Invagen is $500 million and for Exelan it is $50 million.
 
"The acquisition will further strengthen Cipla's presence in US pharmaceutical market. InvaGen's balanced portfolio, robust manufacturing base and strong R&D capabilities will act as lever to expand Cipla's reach in the US market," said Umang Vohra, global chief operating officer.
 
The acquisition is expected to scale to Cipla's US business, currently 8 percent of total revenue and provide a launch pad to introduce its pipeline of products in the respiratory and injectables space, among other products. 
 
This is the second landmark acquisition in Cipla's 80 year history after the one in South Africa.
 
InvaGen pharmaceuticals also provides Cipla about 40 approved abbreviated new drug applications, 32 marketed products, and 30 pipeline products which are expected to be approved over the next four years, the company said.
 
Exelan was incorporated in the year 2011 and is engaged in the business of sales and marketing of generic pharmaceuticals for the government and institutional market.
 
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.

User

India's GDP to grow next fiscal at 7.5%: Moody's

India is relatively less exposed to external factors, including China slowdown and global capital flows

 

US agency Moody's Investors Service on Thursday forecast for India a "stable GDP growth at around 7.5% in 2016 and 2017", saying the country is relatively less exposed to external headwinds, like the Chinese slowdown, and will benefit from lower commodity prices.
 
India is relatively less exposed to external factors, including China slowdown and global capital flows. Instead, the economic outlook will be primarily determined by domestic factors, Moody's said in its report "Global Macro Outlook 2016-17 - Global growth faces rising risks at time of policy constraint".
 
"Together with Turkey and China among the G20 emerging markets, India benefits from lower commodity prices: In 2014, net commodity imports amounted to 5.9% of India's GDP, compared with net exports worth 1.3%, 3.3% and 4.3% for South Africa, Brazil and Indonesia respectively," it said on Thursday.
 
"In the five years to the end of the decade, we expect GDP per capita (at market exchange rates) to increase by 34% in real terms in India, compared with only 3.6% in the G20 emerging markets, excluding China and India," the report added.
 
Instead, the American agency cautioned that India's economic environment is constrained by "banks' balance sheet repair and elevated corporate debt" and the corporate pricing power being constrained by the impact of two consecutive droughts on food price inflation and households budgets.
 
India's economy is powered by sustained growth in consumer spending, fostered by moderate inflation, still favourable demographics and strengthening investment, in particular foreign direct investment, Moody's said.
 
"The 23.55% increase in public sector salaries proposed by the 7th Pay Commission is worth 0.7% of GDP. It is not yet known how this proposal will be implemented but higher public sector wages will most likely contribute to strong consumption growth," the report said.
 
"The pay increase will also probably raise inflationary pressures. However, we assume the government will cut spending in other parts of the budget to maintain the deficit broadly in line with the 3.5% of GDP objective, thereby mitigating some of the inflationary effects," it added.
 
Moody's said overall growth will fail to pick up steam over the next two years as the slowdown in China, lower commodity prices and tighter financing in some countries weigh on the economy.
 
The Indian economy grew 7.3% in the third quarter ended December 31, 2015 -- down from the 7.7% expansion in the previous quarter, but marginally up over the 7.1% over the like period of last fiscal, official data showed last week.
 
Growth was pulled down by lower production in 'agriculture, forestry and fishing', 'electricity, gas and water supply and other utility services' and 'financial, real estate and professional services'.
 
There was a 6% growth in electricity, gas, water supply and other utility services, as against 7.5% growth in the second quarter.
 
The government's mid-year economic review, released in December, lowered the economic growth forecast for the current fiscal to the 7-7.5 percent range, from the previously projected 8.1%-8.5%, mainly because of lower agricultural output due to deficit rainfall.
 
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)